Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

November 13, 2023

View Complete Issue Table of Contents 2019

PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Disclosures

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.

Objective(s)

Principal Faculty

Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.

Select a term to see related articles antivirals baloxavir influenza oseltamivir peramivir Rapivab Relenza Tamiflu Xofluza zanamivir

Superseded by The Medical Letter "Comparison Table: Antiviral Drugs for Seasonal Influenza for 2025-2026 (online only)" - Issue 1740, October 27, 2025

Med Lett Drugs Ther. 2023 Nov 13;65(1689):e1-6 doi:10.58347/tml.2023.1689e

View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024

Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.